Echoing Roger Fan, thank you to everyone that has made this possible, from NEJM and authors to faculty and colleagues. Thrilled to be here!
ProACT seems one of the most pragmatic trials published recently and definitely within the procalcitonin literature. Everything from outcomes (total antibiotic-days and adverse events associated to withholding therapy) to implementation is geared to simulating a real-world scenario and being relevant to clinicians. Focusing on statistical methodology, why did you favor the use of coprimary variables? Does this make it easier or harder to reject the null-hypothesis, especially when compared to composite outcomes? What about regarding clinical relevance? Furthermore, when assessing superiority (total antibiotic-days) and non-inferiority (safety outcome), is it essential to use an intention-to-treat in the former versus a per-protocol analysis in the latter? How do these differ?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.